newsfilter
← Latest News
GlobeNewswire·

Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

Trial to Evaluate AVB-500 as a First-Line Treatment in Combination with Gemcitabine and Nab-Paclitaxel Continues Expansion of AVB-500 in Multiple Oncology Indications and Combinations HOUSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (NASDA